ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IVVD Invivyd Inc

1.91
-0.10 (-4.98%)
May 25 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 460,274
Bid Price 1.80
Ask Price 5.50
News -
Day High 2.03

Low
0.9802

52 Week Range

High
5.195

Day Low 1.92
Company Name Stock Ticker Symbol Market Type
Invivyd Inc IVVD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.10 -4.98% 1.91 00:00:13
Open Price Low Price High Price Close Price Prev Close
2.00 1.92 2.03 1.93 2.01
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,028 460,274 $ 1.98 $ 910,254 - 0.9802 - 5.195
Last Trade Time Type Quantity Stock Price Currency
19:56:22 formt 198 $ 1.91 USD

Invivyd Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
211.42M 110.11M - 0 -198.64M -1.80 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Invivyd News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IVVD Message Board. Create One! See More Posts on IVVD Message Board See More Message Board Posts

Historical IVVD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.402.451.922.18457,402-0.49-20.42%
1 Month2.062.631.922.31457,369-0.15-7.28%
3 Months3.914.741.923.11716,863-2.00-51.15%
6 Months1.465.1951.443.611,240,6860.4530.82%
1 Year1.755.1950.98023.20754,9930.169.14%
3 Years4.705.1950.98023.03556,081-2.79-59.36%
5 Years4.705.1950.98023.03556,081-2.79-59.36%

Invivyd Description

Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19.

Your Recent History

Delayed Upgrade Clock